On March 25, 2014, Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) shares advanced 5.68% in last trading session and ended the day on $7.07. IMMY return on equity ratio is recorded as -47.10% and its return on assets is -44.40%. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) yearly performance is 18.03%.
On Mar 26, 2014, Cesca Therapeutics Inc (NASDAQ:KOOL), an autologous cell based regenerative medicine company, announced it has submitted a pre-IDE (Investigational Device Exemption) information package to the U. S. Food and Drug Administration (FDA) for the use of the SurgWerks(TM) CLI Therapy designed to treat no option patients with late stage critical limb ischemia (CLI). Cesca Therapeutics Inc (NASDAQ:KOOL) shares moved up 5.06% in last trading session and was closed at $1.87, while trading in range of $1.70 – $1.92. Cesca Therapeutics Inc (NASDAQ:KOOL) year to date (YTD) performance is 83.33%.
Rosetta Genomics Ltd. (NASDAQ: ROSG),and Marina Biotech, Inc. (OTCMKTS:MRNA), jointly announced that they had established a strategic alliance, wherein the companies will collaborate to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies. Marina Biotech, Inc. (OTCMKTS:MRNA) weekly performance is 5.77%. On last trading day company shares ended up $1.10. Marina Biotech, Inc. (OTCMKTS:MRNA) distance from 50-day simple moving average (SMA50) is 1.61%. Analysts mean target price for the company is $20.50.
On March 6, 2014, PTC Therapeutics, Inc.(NASDAQ:PTCT) announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. Revenue from grants and collaborations was $4.4 million for the fourth quarter of 2013, compared to $6.6 million for the same period in 2012. Total operating expenses were $22.5 million for the fourth quarter of 2013, including $3.3 million in stock based compensation expense, compared to $12.7 million for the same period in 2012 including $0.5 million in stock based compensation expense. PTC Therapeutics, Inc.(NASDAQ:PTCT) shares after opening at $26.51 on last trade day and at the end of the day closed at $25.10. Company price to sales ratio in past twelve months was calculated as 21.76 and price to cash ratio as 5.30. PTC Therapeutics, Inc. (NASDAQ:PTCT) showed a negative weekly performance of -3.72%.